Drug—target network
By Muhammed A. Yıldırım, Kwang-Il Goh, Michael E. Cusick, Albert-László Barabási, Marc Vidal. Nature Biotechnology, 2007
1,670 citations recorded by the source corpus.
Subfields: Computational Theory and Mathematics, Molecular Biology
View Paper: https://www.semanticscholar.org/paper/7d32468837dd0ad145d9e1b4801b97e078c16544
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Computational Theory and Mathematics
- Brian K. Shoichet
- Yoshihiro Yamanishi
- Jinbo Xu
- John J. Irwin
- Sheng Wang
- Stephen H. Bryant
- Yizhou Yu
- Olivier Bodenreider
In Molecular Biology
- Jinbo Xu
- Sheng Wang
- Roded Sharan
- Arne Elofsson
- Ruth Nussinov
- Trey Ideker
- Yoshihiro Yamanishi
- Peter Csermely
Citations in the corpus
- Docking & Chemoinformatic Screens for New Ligands and Targets (2009, background): “Similarly, Vidal and colleagues adapted network techniques developed for protein–protein association to drug–target associations [47].”
- Machine learning approaches and databases for prediction of drug–target interaction: a survey paper (2020, background): “The following studies were excluded: • studies that do not use machine learning methods for prediction or (e.g. [ 20–25]).”
- Topology Prediction of α-Helical Transmembrane Proteins (2016, background): “For membrane proteins, it is especially imperative to close the gaps between sequences and structures because they are important targets for most commercial drugs [4–6] and only 1-2% of all solved protein structures belong to membrane proteins.”
- Human symptoms–disease network (2014, background): “Most drugs approved by the US Food and Drug Administration are merely palliative 48 , that is, they only treat symptoms rather than targeting disease-specific genes or pathways.”
- Systematic prediction of drug combinations based on clinical side-effects (2014, background): “However such ‘‘magic bullet’’ sometimes shows limited efficacy, especially for complex 4 , which is often due to factors such as network robustness 5 , redundancy 6 , compensatory and neutralizing actions 7 .”
- Structure and dynamics of molecular networks: A novel paradigm of drug discovery: A comprehensive review (2012, methodology): “Currently, there is a broad consensus that this state, where the vast majority of new drugs are related to existing ones, needs to be changed (Section 1.1; Cokol et al., 2005; Yildirim et al., 2007; Iyer et al., 2011a).”